Cannara Reconciled Depreciation vs Research Development Analysis

LOVE Stock

CAD 0.75 0.05 6.25%

Cannara Biotech financial indicator trend analysis is way more than just evaluating Cannara Biotech prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Cannara Biotech is a good investment. Please check the relationship between Cannara Biotech Reconciled Depreciation and its Research Development accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Cannara Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

Reconciled Depreciation vs Research Development

Reconciled Depreciation vs Research Development Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Cannara Biotech Reconciled Depreciation account and Research Development. At this time, the significance of the direction appears to have pay attention.

The correlation between Cannara Biotech's Reconciled Depreciation and Research Development is -0.94. Overlapping area represents the amount of variation of Reconciled Depreciation that can explain the historical movement of Research Development in the same time period over historical financial statements of Cannara Biotech, assuming nothing else is changed. The correlation between historical values of Cannara Biotech's Reconciled Depreciation and Research Development is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Reconciled Depreciation of Cannara Biotech are associated (or correlated) with its Research Development. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Research Development has no effect on the direction of Reconciled Depreciation i.e., Cannara Biotech's Reconciled Depreciation and Research Development go up and down completely randomly.

Correlation Coefficient

-0.94

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Reconciled Depreciation

Research Development

Most indicators from Cannara Biotech's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cannara Biotech current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Cannara Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

At this time, Cannara Biotech's Enterprise Value Over EBITDA is fairly stable compared to the past year. Enterprise Value Multiple is likely to climb to 7.13 in 2024, whereas Selling General Administrative is likely to drop slightly above 9.7 M in 2024.

	2021	2022	2023	2024 (projected)
Gross Profit	17.3M	27.2M	31.3M	32.9M
Total Revenue	35.8M	57.3M	65.8M	69.1M

Gross Profit Total Revenue

Cannara Biotech fundamental ratios Correlations

	Total Assets	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Other Assets	Long Term Debt	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Lease Obligations	Other Stockholder Equity	Total Liab	Net Invested Capital	Total Current Assets	Capital Stock	Net Working Capital	Common Stock	Property Plant Equipment	Other Current Liab	Inventory	Other Current Assets	Intangible Assets
Total Assets		0.89	0.99	0.97	-0.75	0.9	-0.51	0.99	-0.5	0.94	0.88	-0.6	0.94	-0.79	0.84	0.97	1.0	0.95	0.96	0.89	0.95	0.98	-0.86	0.87	0.87	-0.87
Total Current Liabilities	0.89		0.87	0.82	-0.58	1.0	-0.64	0.86	-0.48	0.83	0.98	-0.85	0.83	-0.89	0.73	0.87	0.88	0.87	0.83	0.82	0.8	0.83	-0.76	0.99	0.76	-0.77
Total Stockholder Equity	0.99	0.87		0.99	-0.82	0.89	-0.48	0.99	-0.61	0.87	0.84	-0.56	0.88	-0.72	0.9	0.91	0.99	0.9	0.99	0.84	0.98	0.99	-0.88	0.83	0.83	-0.89
Net Tangible Assets	0.97	0.82	0.99		-0.87	0.85	-0.43	0.99	-0.64	0.85	0.79	-0.46	0.85	-0.67	0.93	0.88	0.97	0.85	0.99	0.8	0.99	0.99	-0.89	0.78	0.85	-0.9
Retained Earnings	-0.75	-0.58	-0.82	-0.87		-0.62	0.38	-0.83	0.81	-0.6	-0.54	0.16	-0.6	0.4	-0.95	-0.61	-0.76	-0.52	-0.89	-0.44	-0.91	-0.85	0.92	-0.53	-0.78	0.91
Accounts Payable	0.9	1.0	0.89	0.85	-0.62		-0.62	0.89	-0.51	0.83	0.98	-0.81	0.84	-0.88	0.77	0.87	0.9	0.87	0.86	0.82	0.84	0.86	-0.78	0.98	0.78	-0.79
Cash	-0.51	-0.64	-0.48	-0.43	0.38	-0.62		-0.55	0.14	-0.53	-0.65	0.61	-0.54	0.74	-0.32	-0.55	-0.52	-0.41	-0.49	-0.26	-0.47	-0.52	0.69	-0.7	-0.54	0.7
Non Current Assets Total	0.99	0.86	0.99	0.99	-0.83	0.89	-0.55		-0.57	0.91	0.85	-0.53	0.91	-0.76	0.88	0.94	0.99	0.89	0.99	0.82	0.98	1.0	-0.92	0.84	0.89	-0.92
Other Assets	-0.5	-0.48	-0.61	-0.64	0.81	-0.51	0.14	-0.57		-0.25	-0.36	0.23	-0.26	0.09	-0.87	-0.31	-0.5	-0.32	-0.68	-0.26	-0.69	-0.57	0.66	-0.4	-0.45	0.66
Long Term Debt	0.94	0.83	0.87	0.85	-0.6	0.83	-0.53	0.91	-0.25		0.89	-0.54	1.0	-0.87	0.65	0.99	0.94	0.93	0.83	0.91	0.82	0.9	-0.77	0.84	0.92	-0.78
Net Receivables	0.88	0.98	0.84	0.79	-0.54	0.98	-0.65	0.85	-0.36	0.89		-0.8	0.89	-0.95	0.66	0.9	0.88	0.88	0.8	0.85	0.78	0.82	-0.74	0.99	0.82	-0.76
Common Stock Shares Outstanding	-0.6	-0.85	-0.56	-0.46	0.16	-0.81	0.61	-0.53	0.23	-0.54	-0.8		-0.54	0.73	-0.37	-0.62	-0.59	-0.69	-0.49	-0.63	-0.44	-0.48	0.42	-0.86	-0.36	0.44
Non Current Liabilities Total	0.94	0.83	0.88	0.85	-0.6	0.84	-0.54	0.91	-0.26	1.0	0.89	-0.54		-0.87	0.66	0.99	0.94	0.93	0.84	0.91	0.83	0.9	-0.77	0.84	0.92	-0.78
Capital Lease Obligations	-0.79	-0.89	-0.72	-0.67	0.4	-0.88	0.74	-0.76	0.09	-0.87	-0.95	0.73	-0.87		-0.46	-0.86	-0.8	-0.8	-0.67	-0.76	-0.65	-0.73	0.67	-0.93	-0.78	0.67
Other Stockholder Equity	0.84	0.73	0.9	0.93	-0.95	0.77	-0.32	0.88	-0.87	0.65	0.66	-0.37	0.66	-0.46		0.69	0.84	0.68	0.94	0.61	0.95	0.89	-0.88	0.67	0.76	-0.87
Total Liab	0.97	0.87	0.91	0.88	-0.61	0.87	-0.55	0.94	-0.31	0.99	0.9	-0.62	0.99	-0.86	0.69		0.97	0.97	0.87	0.92	0.86	0.92	-0.79	0.87	0.88	-0.8
Net Invested Capital	1.0	0.88	0.99	0.97	-0.76	0.9	-0.52	0.99	-0.5	0.94	0.88	-0.59	0.94	-0.8	0.84	0.97		0.94	0.96	0.89	0.95	0.98	-0.87	0.87	0.88	-0.87
Total Current Assets	0.95	0.87	0.9	0.85	-0.52	0.87	-0.41	0.89	-0.32	0.93	0.88	-0.69	0.93	-0.8	0.68	0.97	0.94		0.84	0.98	0.82	0.88	-0.67	0.86	0.77	-0.69
Capital Stock	0.96	0.83	0.99	0.99	-0.89	0.86	-0.49	0.99	-0.68	0.83	0.8	-0.49	0.84	-0.67	0.94	0.87	0.96	0.84		0.76	1.0	0.99	-0.93	0.8	0.85	-0.93
Net Working Capital	0.89	0.82	0.84	0.8	-0.44	0.82	-0.26	0.82	-0.26	0.91	0.85	-0.63	0.91	-0.76	0.61	0.92	0.89	0.98	0.76		0.75	0.81	-0.56	0.8	0.73	-0.57
Common Stock	0.95	0.8	0.98	0.99	-0.91	0.84	-0.47	0.98	-0.69	0.82	0.78	-0.44	0.83	-0.65	0.95	0.86	0.95	0.82	1.0	0.75		0.99	-0.93	0.77	0.85	-0.93
Property Plant Equipment	0.98	0.83	0.99	0.99	-0.85	0.86	-0.52	1.0	-0.57	0.9	0.82	-0.48	0.9	-0.73	0.89	0.92	0.98	0.88	0.99	0.81	0.99		-0.92	0.81	0.89	-0.92
Other Current Liab	-0.86	-0.76	-0.88	-0.89	0.92	-0.78	0.69	-0.92	0.66	-0.77	-0.74	0.42	-0.77	0.67	-0.88	-0.79	-0.87	-0.67	-0.93	-0.56	-0.93	-0.92		-0.75	-0.88	1.0
Inventory	0.87	0.99	0.83	0.78	-0.53	0.98	-0.7	0.84	-0.4	0.84	0.99	-0.86	0.84	-0.93	0.67	0.87	0.87	0.86	0.8	0.8	0.77	0.81	-0.75		0.77	-0.76
Other Current Assets	0.87	0.76	0.83	0.85	-0.78	0.78	-0.54	0.89	-0.45	0.92	0.82	-0.36	0.92	-0.78	0.76	0.88	0.88	0.77	0.85	0.73	0.85	0.89	-0.88	0.77		-0.88
Intangible Assets	-0.87	-0.77	-0.89	-0.9	0.91	-0.79	0.7	-0.92	0.66	-0.78	-0.76	0.44	-0.78	0.67	-0.87	-0.8	-0.87	-0.69	-0.93	-0.57	-0.93	-0.92	1.0	-0.76	-0.88

Click cells to compare fundamentals

Cannara Biotech Account Relationship Matchups

Cannara Biotech fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	54.9M	92.0M	125.6M	141.5M	162.8M	93.7M
Total Current Liabilities	3.5M	6.8M	11.9M	21.2M	24.4M	25.6M
Total Stockholder Equity	38.4M	64.1M	66.7M	79.7M	91.7M	57.0M
Net Tangible Assets	46.9M	38.2M	64.1M	66.7M	76.7M	50.7M
Retained Earnings	(27.1M)	(28.6M)	(26.3M)	(19.3M)	(17.4M)	(18.3M)
Accounts Payable	2.8M	6.2M	8.8M	13.9M	16.0M	16.8M
Cash	7.8M	8.2M	12.1M	4.3M	3.8M	3.7M
Non Current Assets Total	44.3M	72.8M	84.6M	89.8M	103.3M	63.7M
Other Assets	733.8K	514.2K	1.0M	1.2M	1.1M	808.0K
Long Term Debt	12.0M	20.2M	46.2M	39.6M	45.6M	26.2M
Net Receivables	26.4K	2.8M	8.5M	10.6M	12.2M	12.8M
Common Stock Shares Outstanding	737.7M	876.5M	877.0M	90.3M	81.3M	77.2M
Non Current Liabilities Total	13.0M	21.1M	47.0M	40.6M	46.7M	27.1M
Capital Lease Obligations	651.8K	442.5K	236.7K	176.0K	158.4K	150.5K
Other Stockholder Equity	(10.1K)	45.7K	100.1K	15.1K	17.4K	18.3K
Total Liab	16.5M	27.9M	58.9M	61.8M	71.0M	36.2M
Net Invested Capital	50.6M	84.6M	114.9M	125.4M	144.2M	84.8M
Total Current Assets	10.5M	19.2M	41.0M	51.7M	59.5M	30.0M
Capital Stock	58.4M	83.2M	83.3M	88.8M	102.1M	70.5M
Net Working Capital	7.1M	12.4M	29.1M	30.5M	35.1M	20.9M
Common Stock	54.9M	58.4M	83.2M	83.3M	95.8M	65.4M
Property Plant Equipment	39.3M	43.6M	71.7M	83.4M	95.9M	55.4M
Inventory	2.2M	7.4M	19.0M	33.8M	38.8M	40.8M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Cannara Stock Analysis

When running Cannara Biotech's price analysis, check to measure Cannara Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cannara Biotech is operating at the current time. Most of Cannara Biotech's value examination focuses on studying past and present price action to predict the probability of Cannara Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cannara Biotech's price. Additionally, you may evaluate how the addition of Cannara Biotech to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC